Paper Details

  1. Home
  2. Paper Details

Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.

Author: ArasGirish, BaumgartnerScott, KricorianGregory, KruegerJames G, LeonardiCraig, LiJuan, MenterAlan, OrtonneJean-Paul, PappKim A, RussellChris B, ThompsonElizabeth H Z

Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This phase 2, randomized, double-blind, placebo-controlled study assessed the efficacy and safety of brodalumab in 198 patients with moderate to severe plaque psoriasis. Brodalumab significantly improved psoriasis area-and-severity index (PASI) scores compared to placebo at week 12. The most common adverse events were nasopharyngitis, upper respiratory tract infection, and injection-site erythema.
Paper Details　
Original Abstract of the Article :
BACKGROUND: In this phase 2, randomized, double-blind, placebo-controlled, dose-ranging study, we assessed the efficacy and safety of brodalumab (AMG 827), a human anti-interleukin-17-receptor monoclonal antibody, for the treatment of moderate-to-severe plaque psoriasis. METHODS: We randomly assign...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1056/NEJMoa1109017

データ提供：米国国立医学図書館（NLM）

Brodalumab: A Beacon of Hope for Psoriasis

The desert of dermatology is often plagued by the relentless itch and scaling of psoriasis. This research investigates the efficacy and safety of brodalumab, a human anti-interleukin-17-receptor monoclonal antibody, in treating moderate-to-severe plaque psoriasis. Like a well-equipped camel caravan venturing into uncharted territory, this phase 2, randomized, double-blind, placebo-controlled, dose-ranging study aimed to assess the potential of this novel therapy.

The results of this study, my dear readers, are as refreshing as a desert oasis. Brodalumab demonstrated a significant improvement in plaque psoriasis, with a remarkable reduction in PASI scores (a measure of psoriasis severity) compared to placebo. Like a beacon guiding lost travelers, brodalumab showed remarkable efficacy across various dose levels, with a 75% to 90% improvement in PASI scores in some patients.

A New Frontier in Psoriasis Treatment

This study, like a well-worn map, reveals the potential of brodalumab as a promising new treatment for psoriasis. Its efficacy in reducing disease severity and achieving significant improvements in PASI scores suggests that it could become a valuable tool in managing this challenging skin condition.

Navigating the Desert of Skin Disorders

The desert of skin disorders is a harsh landscape to navigate. This research offers hope for those struggling with psoriasis, suggesting that novel therapies like brodalumab can offer significant relief. Remember, my dear readers, taking care of your skin is essential. Stay hydrated, wear protective clothing, and consult with a dermatologist if you experience any concerning skin issues.

Dr.Camel's Conclusion

This study, like a caravan carrying precious goods, brings exciting news for individuals with psoriasis. The remarkable efficacy of brodalumab in reducing disease severity and improving PASI scores provides a beacon of hope for effective treatment. It's a reminder that the desert of dermatology is vast and holds many treasures yet to be discovered.

Date :
  1. Date Completed 2012-04-10
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

22455412

DOI: Digital Object Identifier

10.1056/NEJMoa1109017

Related Literature

Article Analysis
・Effects of brodalumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.